All Journal Guides

Journal Guide

Clinical Infectious Diseases Impact Factor 7.3: Publishing Guide

Infectious disease: diagnosis, treatment, and epidemiology

7.3

Impact Factor (2024)

~25-35%

Acceptance Rate

~90-120 days median

Time to First Decision

What Clin. Infect. Dis. Publishes

Clinical Infectious Diseases published by Oxford University Press is the premier journal for clinical infectious disease research. With JIF 7.3 and Q1 ranking in Infectious Diseases, CID emphasizes rigorous clinical research on infection diagnosis, treatment, and outcomes. The journal publishes research on bacterial, viral, fungal, and parasitic infections. Critically: CID values research with clear clinical relevance and patient impact. Basic microbiology without clinical context is less competitive. The journal seeks papers advancing infection treatment and management.

  • Bacterial infections: pneumonia, sepsis, endocarditis, meningitis
  • Viral infections: HIV, influenza, COVID-19, viral hepatitis
  • Fungal infections: invasive fungal disease, candidiasis, aspergillosis
  • Parasitic infections: malaria, tuberculosis, neglected tropical diseases
  • Antimicrobial resistance: resistance mechanisms, treatment strategies, surveillance
  • Immunocompromised hosts: HIV/AIDS, transplant, cancer patients
  • Infection prevention: vaccination, prophylaxis, infection control
  • Epidemiology: disease transmission, outbreak investigation, risk factors

Editor Insight

CID publishes clinical infectious disease advancing diagnosis and treatment. We seek rigorous studies with patient outcomes and clinical applicability.

What Clin. Infect. Dis. Editors Look For

Clinical finding advancing infection diagnosis or treatment

Present finding improving patient outcomes. Better diagnostic test? Superior treatment? Prevention strategy? Show clinical impact with quantified benefits.

Rigorous clinical data with adequate patient cohort

Sufficient patient numbers and follow-up. Case series, cohort studies, or clinical trials with proper controls.

Mechanistic understanding of infection or treatment response

Explain mechanisms. Why does treatment work? What drives antibiotic resistance? What enables pathogenesis?

Patient outcomes and real-world clinical applicability

Show how findings affect patient outcomes. What does this mean for clinical practice?

Epidemiologic or public health significance

Address broader implications for disease control and population health.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Clin. Infect. Dis.'s editorial review:

Basic microbiology without clinical relevance

CID expects clinical significance. Bacterial or viral studies without patient or treatment connection insufficient.

Small case series without rigorous statistical analysis

Case series valuable but need proper analysis. Multiple patients, clear clinical outcomes, appropriate controls.

No discussion of patient outcomes or clinical implications

Connect to clinical practice. How do findings change patient management?

Inadequate follow-up or outcome documentation

Sufficient follow-up showing outcomes essential. Short-term data without long-term assessment weak.

Ignoring antimicrobial resistance or treatment feasibility

Address resistance patterns and practical treatment considerations.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Clin. Infect. Dis.'s criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Clin. Infect. Dis. Authors

COVID-19 and emerging infection research highly competitive

Clinical research on emerging pathogens and pandemic preparedness receives strong interest.

Antimicrobial resistance and novel antibiotics valued

Resistance mechanisms and new treatment strategies addressing resistance increasingly important.

HIV/AIDS and immunocompromised host research trending

Infection in special populations (HIV, transplant) increasingly prominent.

Real-world evidence and outcomes research gaining importance

Practical treatment outcomes in diverse patient populations increasingly valued.

Diagnostic innovation and rapid testing competitive

Faster, better, cheaper diagnostics have clinical impact.

The Clin. Infect. Dis. Submission Process

1

Manuscript preparation

Prep

5,000-8,000 words with 5-7 figures. Include patient cohort description, infection characterization, diagnostic or treatment data, outcomes, mechanistic discussion.

2

Submission via Oxford system

Day 0

Submit at https://academic.oup.com/cid/. Required: manuscript emphasizing clinical significance, figures showing patient data and outcomes.

3

Editorial assessment

1-2 weeks

Editor assesses clinical novelty and significance. Papers lacking clinical context face rejection. Moderate desk rejection ~25-35%.

4

Peer review

90-120 days

2-3 infectious disease experts assess clinical rigor, significance, and outcomes. First decision 90-120 days.

5

Revision and publication

Revision: 4-8 weeks

Revisions often request additional outcome data or clinical clarification. Publication 2-4 weeks after acceptance.

Clin. Infect. Dis. by the Numbers

2024 Impact Factor6.2
5-Year Impact Factor6.5
Acceptance rate~25-35%
Desk rejection rate~25-35%
Median first decision~105 days
Open access option$3,500 USD
PublisherOxford University Press
Founded1995

Before you submit

Clin. Infect. Dis. accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Clin. Infect. Dis.. ~30 minutes.

Article Types

Clinical Research

5,000-8,000 words

Infectious disease research with clinical outcomes

Brief Report

2,500-4,000 words

Important clinical finding

Landmark Clin. Infect. Dis. Papers

Papers that defined fields and changed science:

  • Antibiotic resistance treatment (various) - multidrug-resistant infections
  • COVID-19 clinical trials (2020+) - pandemic therapeutics
  • Immunocompromised host management (various) - opportunistic infections

Preparing a Clin. Infect. Dis. Submission?

Get pre-submission feedback from reviewers who've published in Clin. Infect. Dis. and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected
Confidential

Primary Fields

Antimicrobial ResistanceImmunocompromised HostsEmerging InfectionsTreatment OutcomesDiagnosis